ReviewTherapeutic advances in respiratory disease2016
The clinical profile of benralizumab in the management of severe eosinophilic asthma.
Review in Therapeutic advances in respiratory disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Efficacy and safety of benralizumab in patients with eosinophilic asthma: a meta-analysis of randomized placebo-controlled trials.Frontiers of medicine · 2018Pooled it
- Advances in the treatment of eosinophilic granulomatosis with polyangiitis.Nature reviews. Rheumatology · 2026Review
- Difficult-To-Treat and Severe Asthma: Can Real-World Studies On Effectiveness of Biological Treatments Change the Lives of Patients?Pragmatic and observational research · 2024Review
- Baseline Characteristics of Patients Enrolled in Clinical Trials of Biologics for Severe Asthma as Potential Predictors of Outcomes.Journal of clinical medicine · 2023Review
- Comparison between clinical trials and real-world evidence studies on biologics for severe asthma.The Journal of international medical research · 2022Review
- Perspectives on the Efficacy of Benralizumab for Treatment of Eosinophilic Granulomatosis With Polyangiitis.Frontiers in pharmacology · 2022Review
- Packaging and Delivery of Asthma Therapeutics.Pharmaceutics · 2021Review
- Plausible Role of Asthma Biological Modifiers in the Treatment of Eosinophilic Esophagitis.Cureus · 2021Article
- The pharmacoeconomics of the state-of-the-art drug treatments for asthma: a systematic review.Multidisciplinary respiratory medicine · 2021Article
- Precision Medicine for Paediatric Severe Asthma: Current Status and Future Direction.Journal of asthma and allergy · 2021Review
- Anti-IL5 Therapies for Severe Eosinophilic Asthma: Literature Review and Practical Insights.Journal of asthma and allergy · 2020Review
- Efficacy and steroid-sparing effect of benralizumab: has it an advantage over its competitors?Drugs in context · 2019Review
- Benralizumab: First Global Approval.Drugs · 2018Review
- Precision Medicine in Targeted Therapies for Severe Asthma: Is There Any Place for "Omics" Technology?BioMed research international · 2018Review
- Severe refractory asthma: current treatment options and ongoing research.Drugs in context · 2018Review
- Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma.BioMed research international · 2018Review
- Benralizumab in the treatment of severe asthma: design, development and potential place in therapy.Drug design, development and therapy · 2018Review
- Innovative treatments for severe refractory asthma: how to choose the right option for the right patient?Journal of asthma and allergy · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite several therapeutic choices, 10-20% of patients with severe uncontrolled asthma do not respond to maximal best standard treatments, leading to a healthcare expenditure of up to 80% of overall costs for asthma. Today, there are new important therapeutic strategies, both pharmacological and interventional, that can result in improvement of severe asthma management, such as omalizumab, bronchial thermoplasty and other biological drugs, for example, mepolizumab, reslizumab and benralizumab. The availability of these new treatments and the increasing knowledge of the different asthmatic phenotypes and endotypes makes correct patient selection increasingly complex and important. In this article, we discuss the features of benralizumab compared with other anti-interleukin-5 biologics and omalizumab, the identification of appropriate patients, the safety profile and future developments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.